Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| EyePoint Inc. | YUTIQ (fluocinolone acetonide intravitreal implant) - (CALM) | Non-infectious uveitis | Phase 3 | Enrollment Conclusion | Intravitreal | Opthalmic |
| EyePoint Inc. | DURAVYU (EYP-1901) - (LUCIA) | wet AMD | Phase 3 | Ongoing | Intravitreal | Opthalmic |
| EyePoint Inc. | EYP-1901 - (VERONA) | Diabetic macular edema (DME) | Phase 3 | Ongoing | Intravitreal injection | Opthalmic |
| EyePoint Inc. | DURAVYU (EYP-1901) - (LUGANO) | Wet age-related macular degeneration (AMD) | Phase 2 | Ongoing | Intravitreal | Opthalmic |
| Fate Therapeutics Inc. | ProTmune - (PROTECT) | Acute graft-versus-host disease (GvHD) undergoing hematopoietic cell transplantation (HCT) | Phase 2 | Trial Discontinued | Intravenous | Immunosuppressant |
| Fennec Pharmaceuticals Inc. | STS-J01 | Non-metastatic solid tumors | Phase 2/3 | Data Released | Intravenous | Oncology |
| FibroBiologics Inc. | CYMS101 | Multiple Sclerosis | Phase 2 | Looking for Funding | Intravenous | Neurology |
| Finch Therapeutics Group Inc. | CP101 - (PRISM-EXT) | C. difficile Infection | Phase 2 | Trial Discontinued | Oral | Antibiotic |
